Article

Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.

Univ Paris-Sud, Faculté des Sciences, Orsay, France.
Gene Therapy (Impact Factor: 4.32). 04/2007; 14(6):533-44. DOI: 10.1038/sj.gt.3302885
Source: PubMed

ABSTRACT The immunogenicity of recombinant adenoviruses (Ad) constitutes a major concern for their use in gene therapy. Antibody- and cell-mediated immune responses triggered by adenoviral vectors hamper long-term transgene expression and efficient viral readministration. We previously reported that interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha play an essential role in both the acute phase and antibody response against Ad, respectively. As TNF-alpha controls the immune response and the development of the immune system, we examined here the consequence of blockade of TNF-alpha activity through Ad-mediated gene delivery of a dimeric mouse TNFR1-IgG fusion protein on transgene expression from a second Ad. Ad encoding TNFR1-IgG (AdTNFR1-Ig) was injected intravenously along with Ad encoding beta-galactosidase or alpha1-antitrypsin transgene in wild-type (IL-6(+/+)) but also in IL-6-deficient mice (IL-6(-/-)) to analyze how TNF-alpha and IL-6 diminish liver gene transfer efficacy. Blockade of TNF-alpha leads to increased transgene expression in both wild-type and IL-6(-/-) mice due to a reduced inflammatory response and to diminished recruitment of macrophages and NK cells towards the liver. Antibody responses against adenoviral particles and expressed transgenes were only delayed in AdTNFR1-Ig-treated wild-type mice, but were markedly reduced in AdTNFR1-Ig-treated IL-6(-/-) mice. Finally, treatment of mice with etanercept, a clinically approved anti-TNF-alpha drug, confirmed the importance of controlling proinflammatory cytokines during gene therapy by adenoviral vectors.

0 Bookmarks
 · 
105 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenovirus (Ad) based gene transfer vectors continue to be the platform of choice for an increasing number of clinical trials worldwide. In fact, within the last five years, the number of clinical trials that utilize Ad based vectors has doubled, indicating growing enthusiasm for the numerous positive characteristics of this gene transfer platform. For example, Ad vectors can be easily and relatively inexpensively produced to high titers in a cGMP compliant manner, can be stably stored and transported, and have a broad applicability for a wide range of clinical conditions, including both gene therapy and vaccine applications. Ad vector based gene transfer will become more useful as strategies to counteract innate and/or pre-existing adaptive immune responses to Ads are developed and confirmed to be efficacious. The approaches attempting to overcome these limitations can be divided into two broad categories: pre-emptive immune modulation of the host, and selective modification of the Ad vector itself. The first category of methods includes the use of immunosuppressive drugs or specific compounds to block important immune pathways, which are known to be induced by Ads. The second category comprises several innovative strategies inclusive of: (1) Ad-capsid-display of specific inhibitors or ligands; (2) covalent modifications of the entire Ad vector capsid moiety; (3) the use of tissue specific promoters and local administration routes; (4) the use of genome modified Ads; and (5) the development of chimeric or alternative serotype Ads. This review article will focus on both the promise and the limitations of each of these immune evasion strategies, and in the process delineate future directions in developing safer and more efficacious Ad-based gene transfer strategies.
    Viruses 09/2010; 2(9):2013-36. · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUD: Bcl-XL, a mitochondria membrane protein, is overexpressed in colorectal cancers and promotes cell survival. We had previously showed that the adenovector expressing small hairpin RNA targeting Bcl-XL could induce significantly apoptosis in colon cancer cells. In this study we wanted to further detect the anti-cancer effect of Ad/Bcl-XL shRNA on the rectal cancer xenografts which were derived from patient tumors. METHODS: We firstly established three rectal cancer xenografts.Then these xenografts were subsequently treated with Ad/Bcl-XL shRNA alone or in combination with 5-fluouracil. Finally, the inhibition of tumor growth, survival time and induction of apoptosis were analyzed. RESULTS: Our results demonstrated that Ad/Bcl-XL shRNA could effectively suppress the tumor growth of all three rectal cancer xenografts and prolong their survival time. After combined with 5-Fu, the suppressing effect of Ad/Bcl-XL shRNA was further enhanced. In addition, our data also showed that Ad/Bcl-XL shRNA combined with 5-Fu could significantly increased the apoptotic ratio in the rectal cancer xenograft. CONCLUSIONS: These data indicated that Ad/Bcl-XL shRNA with or without 5-Fu had effective anti-tumor effects on the patient tumor-derived rectal cancer xenografts, suggesting it could be a potential strategy for rectal cancer therapy. Copyright © 2012 John Wiley & Sons, Ltd.
    The Journal of Gene Medicine 11/2012; · 2.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Helper-dependent adenoviral (HD-Ad) vectors have great potential for gene therapy applications; however, their administration induces acute toxicity that impairs safe clinical applications. We previously observed that PEGylation of HD-Ad vectors strongly reduces the acute response in murine and primate models. To evaluate whether PEGylated HD-Ad vectors combine reduced toxicity with the correction of pathological phenotypes, we administered an HD-Ad vector expressing the human apolipoprotein A-I (hApoA-I) to low-density lipoprotein (LDL)-receptor-deficient mice (a model for familial hypercholesterolemia) fed a high-cholesterol diet. Mice were treated with high doses of HD-Ad-expressing apo A-I or its PEGylated version. Twelve weeks later, LDL levels were lower and high-density lipoprotein (HDL) levels higher in mice treated with either of the vectors than in untreated mice. After terminal killing, the areas of atherosclerotic plaques were much smaller in the vector-treated mice than in the control animals. Moreover, the increase in pro-inflammatory cytokines was lower and consequently the toxicity profile better in mice treated with PEGylated vector than in mice treated with the unmodified vector. This finding indicates that the reduction in toxicity resulting from PEGylation of HD-Ad vectors does not impair the correction of pathological phenotypes. It also supports the clinical potential of these vectors for the correction of genetic diseases.Gene Therapy advance online publication, 25 July 2013; doi:10.1038/gt.2013.38.
    Gene therapy 07/2013; · 4.75 Impact Factor

Full-text (2 Sources)

Download
92 Downloads
Available from
May 22, 2014